Insider Transactions in Q1 2025 at Esperion Therapeutics, Inc. (ESPR)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2025
|
Sheldon L. Koenig President and CEO |
SELL
Open market or private sale
|
Direct |
13,047
-0.82%
|
$13,047
$1.5 P/Share
|
|
Mar 18
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,433
-0.65%
|
$2,433
$1.49 P/Share
|
|
Mar 18
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,535
-0.73%
|
$3,535
$1.48 P/Share
|
|
Mar 14
2025
|
Benjamin Looker General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
224,000
+35.46%
|
-
|
|
Mar 14
2025
|
Eric Warren Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
213,000
+36.36%
|
-
|
|
Mar 14
2025
|
Benjamin Halladay Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
238,000
+32.91%
|
-
|
|
Mar 14
2025
|
Sheldon L. Koenig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
840,000
+34.64%
|
-
|
|
Feb 19
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11
-0.0%
|
$11
$1.86 P/Share
|
|
Feb 19
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
239
-0.15%
|
$239
$1.87 P/Share
|
|
Jan 17
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
123
-0.08%
|
$246
$2.26 P/Share
|
|
Jan 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9
-0.0%
|
$18
$2.27 P/Share
|